Home > Offer to Sell > Pharmaceuticals and Biochemicals > Others > Antiviral Agent Pharmaceutical Raw Materials CAS 3083-77-0 Spongouridine
Antiviral Agent Pharmaceutical Raw Materials CAS 3083-77-0 Spongouridine
Inquiry
| Post Date: | Sep 30,2017 |
| Expiry Date: | Sep 30,2018 |
| Detailed Description: |
details.:ulalee@yuanchengtech.com
,whatsapp: +8618872220744 Spongouridine Basic information Product Name: Spongouridine Synonyms: 1-beta-d-arabinofuranosyl-uraci;3h)-pyrimidinedione,1-beta-d-arabinofuranosyl-4(1h;arauridine;spongouridin;uracilarabinoside;ARABINOSYL-URACIL;ARABINOFURANOSYLURACIL;ARA-U Spongouridine CAS: 3083-77-0 Spongouridine MF: C9H12N2O6 Spongouridine MW: 244.2 Spongouridine EINECS: 221-386-9 Spongouridine Product Categories: Bases & Related Reagents;Carbohydrates & Derivatives;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals Spongouridine Melting point : 220-222°C Spongouridine Storage temp. : 2-8°C Chemical Properties : White to Off-White Solid Usage : Antiviral agent. Used for the treatment of severe acute respiratory syndrome (SARS). Spongouridine Description Vidarabine or 9-β-D-arabinofuranosyladenine (ara-A) is an antiviral drug which is active against herpes simplex and varicella zoster viruses. Clinical indication Vidarabine is an antiviral, active against herpes viruses, poxviruses, rhabdoviruses, hepadnaviruses and some RNA tumour viruses. A 3% ophthalmic ointment Vira-A is used in the treatment of acute keratoconjunctivitis and recurrent superficial keratitis caused by HSV-1 and HSV-2. Vidarabine is also used to treat herpes zoster in AIDS patients, reducing lesions formation and the duration of viral shedding. Many of the previous uses of vidarabine have been superseded by acyclovir, due to the hospitalisation required for intra venous dosing, and acyclovir has a higher selectivity, lower inhibitory concentration and higher potency. Toxic side effects are rare, but have been reported with high concentrations of vidarabine, such as nausea, vomiting, leukopenia and thrombocytopenia in patients receiving high intravenous doses daily. |
| Company: | hubei gongchuang ltd.c [ China ] |
| Contact: | ulalee |
| Tel: | +86-571-15784251 |
| Fax: | |
| Email: | gcgj11@ycphar.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
